Informed Prostate Cancer Patient Support

A blood test that screens for multiple cancers at once promises to boost early detection

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment - MarketWatch

Genetic Score Predicts Risk of Lethal Prostate Cancer : Researchers at UC San Diego report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer, which kills more than 34,000 men in the U.S. annually.

Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents | bioRxiv

Cross-Modality Image Registration Using a Training-Time Privileged Third Modality | IEEE Journals & Magazine | IEEE Xplore

  Radiotherapy Plus Hormone Therapy Boosts Prostate Cancer Outcomes medscape.com Radiotherapy Plus Hormone Therapy Boosts Prostate Cancer Outcomes Liam Davenport 4 minutes SAN ANTONIO — Adding metastasis-directed therapy (MDT) to intermittent hormone therapy significantly improved progression-free survival (PFS) in patients with oligometastatic prostate cancer , allowing patients relief from hormone therapy, researchers found. More specifically, the combination therapy was associated with a 75% increase in PFS compared with hormone therapy alone as well as a significant increase in the time men spent with normal, or eugonadal, testosterone levels. Results from the phase 2 randomized basket trial suggest that combining MDT with intermittent hormone therapy helps maintain "excellent disease control in men with oligometastatic prostate cancer" and allows for "time off from

Lower PSA Screening Rates Linked to Rise in Mets Prostate Cancer : Should national guidelines on PSA screening be revisited after an analysis found that a decrease in screening was associated with an increase in metastatic prostate cancer incidence? medscape.com Lower PSA Screening Rates Linked to Rise in Mets Prostate Cancer Liam Davenport 3-4 minutes SAN ANTONIO — Veterans Administration (VA) medical centers with lower prostate-specific antigen (PSA) screening rates reported higher rates of metastatic prostate cancer , a recent retrospective analysis found. Across 128 VA facilities, PSA screening rates fell from 47.2% in 2005 to 37% in 2019, while metastatic prostate cancer incidence increased from 5.2 per 100,000 to 7.9 per 100,000 men in that time. The current study is "very important because it showed that in groups of patients where screening was not encouraged or not practiced,

Why Are Cancer Rates Rising For Those Under 50? (VIDEO) newsy.com Why Are Cancer Rates Rising For Those Under 50? Lindsey Theis 6-7 minutes More people are getting diagnosed with cancer, especially those under 50 — but why? At 41 years old Barney Morris was thriving.   "I was a federal agent at the time, moving up the ladder rapidly. I was a major in the U.S. Air Force," he said.  But that all came to a crashing halt at his  annual check-up  when his doctor gave him the shocking news — he had prostate cancer.   "I thought I was in perfect health. I had absolutely no symptoms," said Morris.   A recent study in the  journal Nature  found prostate cancer is among 14 different cancers rising among adults under 50 at an alarming rate. Breast, colorectal, endometrial and esophageal, head and neck, pancreatic, liver, stomach, thyroid and multiple myeloma cancers significantly in

Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated with Dose-Escalated Radiotherapy - ScienceDirect : Prognostic factors for prostate cancer include TNM stage, pre-treatment PSA, pathology (via Gleason score (GS) or Grade Group). Of these, Gleason scor…

Low Rates of PSA Screening Linked to Increase in Metastatic Prostate Cancer | MedPage Today

Shorter Course of Radiation Therapy Proves Mettle in High-Risk Prostate Cancer | MedPage Today

How to Self-Advocate for Advanced Prostate Cancer

Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases

18F‐DCFPyL positron emission tomography/magnetic resonance imaging‐guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis - Niu - The Prostate - Wiley Online Library

The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer - ScienceDirect

Diet Tips for Advanced Prostate Cancer As you go through prostate cancer treatment, there are foods you can eat -- and others to avoid -- that can boost your health. Although there's no magic diet cure for prostate cancer, your eating habits can make a difference in your outlook. "Across all cancers, and especially prostate cancer, a heart-healthy, sensible, and modest sugar intake diet is absolutely helpful for cancer care," says Mark Pomerantz, MD. He's a medical oncologist at the Center for Genitourinary Oncology at the Dana-Farber Cancer Institute. Treatments for prostate cancer can affect your metabolism (how food is turned into energy), strength, and stamina, he says. When you eat foods that support your heart and improve your overall health, your body can handle those treatments better. "Along with exercise, a diet that helps you maintain as lean a body as possible is very valuable and assists in our ability to treat advanced prostate cancer a

High-Dose-Rate Brachytherapy Boost in Prostate Cancer Improves QOL | MedPage Today

How Does Exercise Benefit Men With Prostate Cancer?

How Early Can Imaging Assess Response in End-Stage Prostate Cancer? medscape.com How Early Can Imaging Assess Response in End-Stage Prostate Cancer? Becky McCall 4 minutes BARCELONA, Spain ― Using 177 Lu-PSMA (prostate-specific membrane antigen) SPECT to monitor tumor response at week 12 after the third dose of the targeted radioligand 177 Lu-PSMA-617 (Pluctivo, Novartis) has potential as an early predictive biomarker for men with end-stage metastatic castration-resistant prostate cancer (mCRPC), according to data reported at the European Association of Nuclear Medicine (EANM) 2022 meeting. The same researcher suggests that 177 Lu-PSMA SPECT, if used even earlier, after only 6 weeks, might also be a reliable biomarker. Such early imaging biomarkers might help determine intensification or deintensification of therapy to the benefit of patients for whom time and quality of life have added

Merck pays Moderna $250m for personalized cancer vaccine

Shortened Course of Radiation Therapy Safe and Effective for Men with High-risk Prostate Cancer | Imaging Technology News : Phase III study provides randomized evidence of equivalent outcomes and side effects with 5 vs. 8 weeks of radiation for high-risk disease

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial - ScienceDirect

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect

The latest in cancer treatments - Harvard Health health.harvard.edu The latest in cancer treatments - Harvard Health 6-8 minutes What’s new for the most common cancers among men? More effective cancer treatments are ongoing goals in medicine. Labs and research trials continue to identify new strategies that help treat cancer earlier and improve outcomes. So, what has sparked the most interest lately in the areas of prostate, lung, and colon cancer—the most common cancers among men? For insight, we turned to three oncologists from the Harvard-affiliated Dana-Farber Cancer Institute to share what stands out in their respective fields. The experts are Dr. Alicia Morgans, a genitourinary oncologist; Dr. Jacob Sands, a thoracic oncologist; and Dr. Chris Manz, a gastrointestinal oncologist. Here’s what the

Study Offers New Hope for Treatment-Resistant Prostate Cancer - Florida Hospital News and Healthcare Report

Study Offers New Hope for Treatment-Resistant Prostate Cancer

VA pauses electronic health record system rollout | The American Legion

Electronic Medical Records Are Strangling American Medicine | MedPage Today medpagetoday.com Electronic Medical Records Are Strangling American Medicine Dane Brodke, MD, MPH 7-8 minutes Opinion > Second Opinions — The implications for burnout are staggering by October 23, 2022 Last month, 15,000 nurses went on strike in Minnesota in the largest private-sector nursing strike in U.S. history. They were protesting understaffing and overwork at a time when provider burnout has reached epidemic proportions -- approximately 63% of physicians and 80% of nurses now report symptoms of burnout. Meanwhile, healthcare continues to struggle with overwhel

ADT Timing with Radiation Therapy Influences Outcomes for Men with Prostate Cancer — Cancer ABCs cancerabcs.org ADT Timing with Radiation Therapy Influences Outcomes for Men with Prostate Cancer — Cancer ABCs 2-3 minutes Generally, it is accepted that men with prostate cancer who elect to have radiation as their primary treatment benefit from also having short-term androgen deprivation therapy (ADT).  Historically, ADT is used before beginning radiation.  In a recent extensive analysis of over 7,400 men with data from 12 international randomized trials, it has been shown that it is optimal for men to begin ADT when starting radiation. This way, most of the period of low testoster

Reconstructing protein interactions at enhancer-promoter regions in prostate cancer | bioRxiv

Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experience - Satapathy - The Prostate - Wiley Online Library

Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes—ready for prime time? | Prostate Cancer and Prostatic Diseases Nadine A. Friedrich , Stephen J. Freedland & Ilona Csizmadi   Prostate Cancer and Prostatic Diseases ( 2022 ) Cite this article Metrics details Intensive research has aimed to identify modifiable dietary factors to reduce prostate cancer (PC) risk and improve outcomes, but the evidence for these strategies remains inconclusive [ 1 ]. Plant-based dietary patt

High PSMA Predictive of Good Response to Radioisotope Therapy in Prostate Cancer | MedPage Today : But expert says trial findings might be more meaningful with OS focus

Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer | Scientific Reports

High PSMA Predicts Targeted Therapy Response in Prostate Cancer

The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited - Beyond the Abstract

EAU 2022: Recurrent Prostate Cancer: Treatment Landscape of Hormone Sensitive Recurring M1 Prostate Cancer

AUA 2022: State-of-the-Art Lecture: PSMA Diagnostics and Theranostics

ASCO 2022: Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials

The Future of PSMA PET and WB MRI as Next-Generation Imaging Tools in Prostate Cancer - Beyond the Abstract

Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?

ASCO 2022: Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial PSMA SRT

ASCO 2022: Circulating Tumour Cells and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 Plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer

Post-Diagnostic Health Behaviour Scores in Relation to Fatal Prostate Cancer - Beyond the Abstract

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer | Novartis novartis.com Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer 12-15 minutes Oct 14, 2022 Phase III VISION trial showed Pluvicto ® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC 1 Approximately 473,000 prostate cancer cases and 108,000 prostate cancer-related deaths occurred across Europe in 2020 2 ; Metastatic prostate cancer has a 5-year survival rate of approximately 30% 3 Two Phase III trials are underway to evaluate Pluvicto ® for treatment in earlier stages of metastatic prostate cancer Basel, October 14, 2022 — Novartis announced today that the Committee for Medic